Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lena...
Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
About this item
Full title
Author / Creator
Publisher
United States: John Wiley and Sons Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley and Sons Inc
Subjects
More information
Scope and Contents
Contents
ABSTRACT
Objective
We report the results of a pilot study investigating the combination of brentuximab vedotin (BV) and lenalidomide in patients with relapsed/ refractory T‐cell lymphoma.
Methods
A dose escalation study design was utilized. Primary and secondary endpoints included maximum tolerated dose (MTD), adverse events, and respon...
Alternative Titles
Full title
Assessment of the Tolerability and Optimal Dosing of the Combination of Brentuximab Vedotin and Lenalidomide in Patients With Relapsed or Refractory T‐cell Lymphoma: Results of a Single‐centre Phase 1 Dose‐escalation Study
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_a96172422f7946b0ace526868758e5bd
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_a96172422f7946b0ace526868758e5bd
Other Identifiers
ISSN
2688-6146
E-ISSN
2688-6146
DOI
10.1002/jha2.70033
